Edesa Biotech's Paridiprubart Shows Promise in Inhibiting Inflammation from Influenza and Other Pathogens

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study demonstrated that inflammation signaling from multiple pathogens, including Influenza A, coronavirus, and a common bacterium (H. influenzae), was inhibited by Edesa's TLR4 antagonist, paridiprubart. These findings support ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 29.
  • textsms

U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen has received approval from the US Food and Drug Administration (FDA) for Bylvay, a drug used to treat cholestatic pruritus in patients with Alagille syndrome aged 12 months or older. This marks the second rare cholestatic liver disease indication for Bylvay in the US after progressive familial intrahepatic cholestasis related pruritus in 2021. The approval was based on positive data from t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Sumitomo Pharma Oncology, Inc. has presented updated preliminary data from a Phase 1/2 clinical study evaluating TP-3654 at the European Hematology Association 2023 Hybrid Congress. The investigational selective oral PIM1 kinase inhibitor is being tested in patients with myelofibrosis who were previously treated with or ineligible for JAK inhibitor therapy. Preliminary data showed spleen volume ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Sumitomo Pharma Oncology, Inc. has presented updated preliminary data from its ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy. The initial preliminary data was presented at the American Society of Hematology (ASH) Annual Meeting & Exposition 20..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms